#2020ESMO# 这个比较有意思，
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Date 23.09.2020
①
Is Osimertinib the best single agent if 1st line?
Lecture Time
13:00 - 13:15
Speakers
Myung-Ju Ahn (Seoul, Korea, Republic of)
②
Should chemotherapy be combined upfront with EGFR TKI?
Lecture Time
13:15 - 13:30
Speakers
Ross Soo (Singapore, Singapore)
③
Is a combination of anti-angiogenic with EFGR TKI a new standard
Lecture Time
13:30 - 13:45
Speakers
Martin Reck (Grosshansdorf, Germany)
④
Do immune check point work in EGFR TKI?
Lecture Time
13:45 - 14:00
Speakers
Edward B. Garon (Santa Monica, CA, United States of America)
⑤
In a multiline setting, what is the best sequencing?
Lecture Time
14:00 - 14:10
Speakers
Enriqueta Felip (Barcelona, Spain)